US · SIGA
SIGA Technologies, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- New York City, NY 10065
- Website
- siga.com
Price · as of 2024-12-31
$4.60
Market cap 463.33M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $29.27 | +536.3% |
| Intrinsic Value(DCF) | $3.37 | -26.74% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $6.12 | +33.07% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $8.98 | $30.51 | $27.63 | $0.00 | $0.00 |
| 2011 | $2.12 | $114.48 | $0.13 | $2.13 | $0.00 |
| 2012 | $3.17 | $57.90 | $0.00 | $0.00 | $5.68 |
| 2013 | $2.42 | $120.70 | $0.00 | $0.00 | $9.44 |
| 2014 | $1.80 | $33.68 | $0.00 | $0.00 | $164.96 |
| 2015 | $0.45 | $44.97 | $0.00 | $0.00 | $0.00 |
| 2016 | $2.33 | $322.18 | $0.00 | $0.00 | $0.00 |
| 2017 | $4.38 | $33.16 | $0.00 | $0.00 | $4.27 |
| 2018 | $4.41 | $721.71 | $14,234.69 | $27.66 | $19,166.48 |
| 2019 | $3.90 | $40.58 | $0.90 | $0.75 | $7.34 |
| 2020 | $5.09 | $147.03 | $0.13 | $5.18 | $255.46 |
| 2021 | $5.10 | $40.04 | $0.18 | $6.91 | $13.67 |
| 2022 | $4.22 | $24.37 | $0.00 | $0.00 | $0.00 |
| 2023 | $4.10 | $29.17 | $1.27 | $0.76 | $31.84 |
| 2024 | $5.15 | $29.27 | $1.50 | $0.00 | $6.12 |
AI valuation
Our deep-learning model estimates SIGA Technologies, Inc.'s (SIGA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $29.27
- Current price
- $4.60
- AI upside
- +536.3%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3.37
-26.74% upside
Graham-Dodd
—
— upside
Graham Formula
$6.12
+33.07% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SIGA | SIGA Technologies, Inc. | $4.60 | 463.33M | +536% | -27% | — | +33% | 6.20 | 1.70 | 2.65 | 3.01 | — | 1.71 | 77.44% | 50.45% | 42.69% | 28.70% | 100.67% | 23.75% | 0.00 | — | 9.12 | 6.97 | -2.20 | -1263.00% | -86.00% | -4860.00% | 13.27% | 1.92 | 90.03% | 11.62% | 72.10% | 13.06% | 3.03 | 4.36 | 1.53 | 10.11 |
| AQST | Aquestive Therapeutics, I… | $4.00 | 397.23M | +466% | -73% | — | — | -5.21 | -3.82 | 3.99 | -7.37 | -1.78 | -3.82 | 68.95% | -53.46% | -76.68% | 52.97% | 32.25% | -55.57% | -0.63 | -1.83 | 4.68 | 4.18 | 1.26 | 29231.00% | 1380.00% | 38702.00% | -15.63% | -1.90 | 37.66% | 0.00% | 0.00% | 18.71% | -6.38 | -5.46 | 3.41 | -3.77 |
| CTMX | CytomX Therapeutics, Inc. | $5.37 | 909.87M | +2,414% | -87% | -65% | +202% | 1.76 | -123.14 | 0.41 | -1.31 | — | -28.25 | 100.00% | 18.10% | 23.08% | -133.06% | -16.56% | 19.77% | -20.58 | — | 1.25 | 1.21 | -1.07 | -503506.00% | 3645.00% | 5216.00% | -154.12% | -1.01 | 57.76% | 0.00% | 0.00% | 45.36% | -1.40 | 0.41 | -0.25 | -5.71 |
| DRIO | DarioHealth Corp. | $11.97 | 80.9M | +162% | -51% | — | — | -22.91 | 13.60 | 36.23 | -19.50 | — | -234.90 | 49.06% | -213.55% | -158.09% | -65.68% | -88.81% | -39.71% | 0.42 | -601.50 | 2.44 | 2.03 | -0.05 | -6839.00% | 3286.00% | 2499.00% | -3.95% | -2.32 | -62.10% | 0.00% | 0.00% | 0.00% | -16.99 | -25.36 | 36.29 | 6.81 |
| EBS | Emergent BioSolutions Inc… | $8.15 | 434.81M | +481% | -56% | +80% | — | 9.14 | 0.92 | 0.65 | 3.56 | — | 5.59 | 48.62% | 13.47% | 7.08% | 10.46% | 6.53% | 3.88% | 1.09 | 1.69 | 5.01 | 2.19 | 1.54 | -12583.00% | -2881.00% | 33799.00% | 32.60% | 1.29 | 16.09% | 0.00% | 0.00% | 48.82% | 8.47 | 5.41 | 1.14 | 1.49 |
| ESPR | Esperion Therapeutics, In… | $3.35 | 661.73M | +1,302% | +27,124% | — | — | -6.11 | -0.81 | 0.95 | 100.78 | — | -0.81 | 79.36% | 16.37% | -15.57% | 12.27% | 177.11% | -18.83% | -1.52 | 0.92 | 1.37 | 0.91 | 58.98 | -8621.00% | 18566.00% | -8231.00% | -7.58% | -0.10 | -78.04% | 0.00% | 0.00% | 3.87% | 14.02 | -31.82 | 2.30 | -4.45 |
| OLMA | Olema Pharmaceuticals, In… | $24.20 | 1.9B | — | — | — | — | -2.09 | 0.66 | — | 1.14 | -74.60 | 0.66 | 0.00% | — | — | -39.07% | 974.77% | -35.57% | 0.00 | — | 10.50 | 10.45 | 0.97 | 280.00% | — | 2482.00% | -38.59% | -2.50 | 716.12% | 0.00% | 0.00% | 26.56% | 1.14 | 1.55 | — | 2.53 |
| ORGO | Organogenesis Holdings In… | $3.21 | 407.39M | +1,529% | +5,869% | -5% | +241% | 10.27 | 1.27 | 0.67 | 5.43 | — | 1.45 | 73.57% | 7.92% | 10.09% | 10.81% | 15.37% | 6.75% | 0.27 | 19.59 | 3.62 | 3.11 | -0.17 | -160000.00% | 1704.00% | -68573.00% | -6.43% | -0.10 | -8.41% | 2.99% | 30.70% | 2.99% | 8.25 | -15.07 | 0.65 | 3.09 |
| RIGL | Rigel Pharmaceuticals, In… | $34.74 | 630.58M | +1,555% | +15% | -85% | +70% | 20.63 | 109.71 | 2.01 | 12.04 | — | -15.15 | 89.60% | 13.49% | 9.75% | -137.92% | -117.91% | 12.44% | 18.24 | 3.06 | 2.13 | 1.88 | 0.11 | -16875.00% | 5338.00% | -24981.00% | 8.61% | 0.50 | -159.09% | 0.00% | 0.00% | 9.58% | 14.19 | 11.05 | 1.92 | -8.42 |
| SNDL | SNDL Inc. | $1.54 | 396.55M | +1,401% | +62% | -9% | — | -5.99 | 0.51 | 0.63 | -11.63 | — | 0.61 | 26.11% | -11.28% | -10.30% | -8.20% | -8.54% | -6.82% | 0.13 | -13.49 | 5.10 | 3.06 | 1.60 | -4162.00% | 126.00% | -27858.00% | 7.62% | 0.61 | 3.96% | 0.00% | 0.00% | 8.92% | -4.62 | 10.92 | 0.52 | 0.99 |
| VTYX | Ventyx Biosciences, Inc. | $13.97 | 1B | — | — | — | — | -0.76 | 0.40 | — | 0.71 | — | 0.40 | 0.00% | — | — | -54.27% | -573.99% | -48.76% | 0.04 | — | 17.97 | 17.09 | 0.11 | -4030.00% | — | -2151.00% | -128.50% | -10.24 | -506.96% | 0.00% | 0.00% | 0.00% | 0.70 | 0.80 | — | -0.92 |
About SIGA Technologies, Inc.
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
- CEO
- Diem Nguyen
- Employees
- 46
- Beta
- 0.98
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3.37 ÷ $4.60) − 1 = -26.74% (DCF, example).